Firebrick Pharma’s Phase 3 Trial of Nasodine Resumes
Posted: 23 March 2023 Firebrick Pharma Limited is pleased to announce that its Phase 3 clinical trial of Nasodine Nasal Spray (Nasodine) as a treatment for the common cold has received the necessary ethics approvals to re-open for…
ANDHealth Announces Partnership with Brandon BioCatalyst for $50m BioMedtech Incubator
Posted: 21 March 2023 We are delighted to announce that, ANDHealth, in partnership with Brandon BioCatalyst, has been selected by the Medical Research Future Fund to deliver the $50m BioMedTech Incubator Program (BMTI). This investment substantially increases the combined non-dilutive…
Cardihab developing intuitive AI driven analytics solution set to revolutionise patient care
Posted: 21 March 2023 Healthcare providers and patients will soon benefit from an intuitive health data analytics product called C.R.O.P.S which is designed to unlock insights gained from digital health platform Cardihab®. Brisbane-based digital health company Cardihab, provides…
Moderna Australia Fellowship
Posted: 20 March 2023 Moderna Australia is proud to help develop the country’s world-leading health and medical research sector and the next generation of Australian-based scientists through the Moderna Australia Fellowship Program. This annual program will prioritise research…
FDA Approves Expanded Indication for Telix’s Illuccix to Include Patient Selection for PSMA-Directed Radioligand Therapy
Posted: 17 March 2023 Telix Pharmaceuticals today announces that the United States Food and Drug Administration (FDA) has approved a supplementary New Drug Application (sNDA) for Illuccix® (kit for the preparation of gallium Ga 68 gozetotide injection) to enable…
Alterity Therapeutics Enrolls First Patient in the U.S. in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy
Posted: 17 March 2023 Alterity Therapeutics, a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, announced the first participant has been dosed in the U.S. in the Company’s Phase 2 clinical trial of ATH434 in…
Cynata Adds New Sites for DFU Clinical Trial
Posted: 17 March 2023 Cynata Therapeutics Limited, a clinical-stage biotechnology company specialising in cell therapeutics, has announced that three additional clinical sites have opened for recruitment in the ongoing clinical trial of CYP-006TK in patients with diabetic foot…
Smart nanotechnology for more accurate delivery of insulin
Posted: 16 March 2023 More efficient and longer lasting glucose-responsive insulin that eliminates the need for people with type 1 diabetes to measure their glucose levels could be a step closer thanks to a Monash University-led project. Published…
Women-led startup innovations in pregnancy monitoring, clinical trials supported by $750,000 University investment
Posted: 16 March 2023 The University of Melbourne will provide pre-seed investment to support two innovative female-founded healthcare startups, innovative at-home pregnancy monitoring start-up Kali Healthcare, and clinical trial participant recruitment start-up Torch Recruit. Kali Healthcare, co-founded by…
Immutep Announces Initiation of Phase II/III Trial for Eftilagimod Alpha plus Paclitaxel in Metastatic Breast Cancer
Posted: 16 March 2023 Immutep Limited, a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, announced the initiation of AIPAC-003 (Active Immunotherapy, Eftilagimod Alpha, and PAClitaxel), an integrated Phase II/III trial to evaluate eftilagimod alpha (“efti”)…
Pfizer and BioNTech Receive U.S. Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Booster in Children Under 5 Years
Posted: 16 March 2023 Pfizer Inc. and BioNTech SE announced today that the U.S. Food and Drug Administration (FDA) granted emergency use authorization (EUA) to provide a single booster dose of the companies’ Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine…
Extension for project tackling antimicrobial resistance in PNG
Posted: 15 March 2023 A major project tackling antimicrobial resistance (AMR) in Papua New Guinea has been extended until December 2023. The Fleming Fund Country Grant – Papua New Guinea (PNG) is led by Burnet Institute working in close collaboration…
